BriaCell Therapeutics Corp. (BCTX)
4.92
-0.28 (-5.38%)
Apr 25, 2025, 3:59 PM - Market open
-5.38% (1D)
| Bid | 3.61 |
| Market Cap | 18.23M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -11.59M |
| EPS (ttm) | -4.75 |
| PE Ratio (ttm) | -1.03 |
| Forward PE | -2.88 |
| Analyst | Buy |
| Ask | 6.19 |
| Volume | 348,967 |
| Avg. Volume (20D) | 1,471,481 |
| Open | 5.01 |
| Previous Close | 5.20 |
| Day's Range | 4.82 - 5.05 |
| 52-Week Range | 0.35 - 9.82 |
| Beta | 1.71 |
About BCTX
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immun...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 14, 2012
Employees 16
Stock Exchange NASDAQ
Ticker Symbol BCTX
Website https://www.briacell.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BCTX stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 551.07% from the latest price.
Stock Forecasts2 days ago
-13.76%
BriaCell Therapeutics shares are trading lower aft...
Unlock content with
Pro Subscription
3 days ago
+11.05%
BriaCell Therapeutics shares are trading higher after the company announced it confirmed the sustained complete resolution of the lung metastasis two months after initial treatment in the ongoing Phase 1/2 Bria-OTS study.
